InflaRx announces new izicopan pre-clinical data

InflaRx (IFRX) announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk. Izicopan is an investigational oral C5aR1 inhibitor designed to achieve differentiated pharmacological properties. In a head-to-head in vitro study using a standard glutathione trapping assay in human liver microsomes, izicopan demonstrated minimal reactive metabolite formation, with conjugate remaining low throughout the incubation period. These findings support a low level of bioactivation in this assay system. Under the same experimental conditions, avacopan showed higher levels of thiol adducts, including both glutathione and downstream cysteine conjugates, consistent with more extensive oxidative bioactivation. Differences in total reactive conjugate peak areas were most pronounced at early time points and remained observable over the course of the assay. Overall, these results suggest a lower extent of reactive intermediate formation for izicopan in this experimental setting. While in vitro findings do not directly predict clinical outcomes, InflaRx believes these results support the differentiated profile of izicopan.